Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients

Clinical Microbiology and Infection

Volumn 21, Issue 7, 2015, Pages 710.e1-710.e9

  Wiegand, S B ^a,b   Jaroszewicz, J ^a,c   Potthoff, A ^a   Honer zu Siederdissen C ^a   Maasoumy, B ^a   Deterding, K ^a   Manns, M P ^a,b   Wedemeyer, H ^a,b   Cornberg, M ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b German Center for Infectious Diesease (DZIF)   (Germany)

^c MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Hepatitis B; Hepatitis B surface antigen; Hepatitis B virus hepatitis C virus coinfection; Hepatitis C; Interferon induced protein 10

Indexed keywords

GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPATITIS B SURFACE ANTIGEN; NUCLEOTIDE; VIRUS RNA; CXCL10 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; INVESTIGATIVE PROCEDURES; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; VIRUS REPLICATION; ADOLESCENT; AGED; BLOOD; CHEMISTRY; COMPLICATION; CROSS-SECTIONAL STUDY; HEPACIVIRUS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; SERUM; VIRUS INTERFERENCE; YOUNG ADULT;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ADOLESCENT; ADULT; AGED; CHEMOKINE CXCL10; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; SERUM; VIRAL INTERFERENCE; VIRUS REPLICATION; YOUNG ADULT;

EID: 84930818747     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.03.003     Document Type: Article

References (38)

1. Chu C.-J., Lee S.-D. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008, 23:512-520.
2. Potthoff A., Manns M.P., Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother 2010, 11:919-928.
3. Raimondo G., Brunetto M.R., Pontisso P., Smedile A., Maina A.M., Saitta C., et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology 2006, 43:100-107.
4. Pontisso P., Ruvoletto M.G., Fattovich G., Chemello L., Gallorini A., Ruol A., et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1993, 105:1529-1533.
5. Saitta C., Pontisso P., Brunetto M.R., Fargion S., Gaeta G.B., Niro G.A., et al. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy. Antivir Ther 2006, 11:931-934.
6. Potthoff A., Wedemeyer H., Boecher W.O., Berg T., Zeuzem S., Arnold J., et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-α2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol 2008, 49:688-694.
7. Liu C.-J., Chuang W.-L., Lee C.-M., Yu M.-L., Lu S.-N., Wu S.-S., et al. Peginterferon-α2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology 2009, 136:496-504.e3.
8. Webster D.P., Klenerman P., Dusheiko G.M. Hepatitis C. Lancet 2015, 385(9973):1124-1135. 10.1016/S0140-6736(14)62401-6.
9. Potthoff A., Berg T., Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-α2b and ribavirin. Scand J Gastroenterol 2009, 44:1487-1490. HEP-NET B/C Coinfection Study Group.
10. Shih C.M., Lo S.J., Miyamura T., Chen S.Y., Lee Y.H. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells. J Virol 1993, 67:5823-5832.
11. Shih C.M., Chen C.M., Chen S.Y., Lee Y.H. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995, 69:1160-1171.
12. Schüttler C.G., Fiedler N., Schmidt K., Repp R., Gerlich W.H., Schaefer S. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein. J Hepatol 2002, 37:855-862.
13. Chen S.-Y., Kao C.-F., Chen C.-M., Shih C.-M., Hsu M.-J., Chao C.-H., et al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein. J Biol Chem 2003, 278:591-607.
14. Bellecave P., Gouttenoire J., Gajer M., Brass V., Koutsoudakis G., Blum H.E., et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatol Baltim Md 2009, 50:46-55.
15. Chan H.L.-Y., Thompson A., Martinot-Peignoux M., Piratvisuth T., Cornberg M., Brunetto M.R., et al. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011, 55:1121-1131.
16. Jaroszewicz J., Calle Serrano B., Wursthorn K., Deterding K., Schlue J., Raupach R., et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010, 52:514-522.
17. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012, 57:167-185.
18. Cornberg M., Jaroszewicz J., Manns M.P., Wedemeyer H. Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 2010, 56:451-465.
19. Jaroszewicz J., Reiberger T., Meyer-Olson D., Mauss S., Vogel M., Ingiliz P., et al. Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection. PloS One 2012, 7:e43143.
20. Brunetto M.R., Moriconi F., Bonino F., Lau G.K.K., Farci P., Yurdaydin C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon-α2a in HBeAg-negative chronic hepatitis B. Hepatol Baltim Md 2009, 49:1141-1150.
21. Zoutendijk R., Hansen B.E., van Vuuren A.J., Boucher C.A.B., Janssen H.L.A. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011, 204:415-418.
22. Cornberg M., Höner Zu Siederdissen C. HBsAg seroclearance with NUCs: rare but important. Gut 2014, 63:1208-1209.
23. Jaroszewicz J., Ho H., Markova A., Deterding K., Wursthorn K., Schulz S., et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011, 16:915-924.
24. Papatheodoridis G., Goulis J., Manolakopoulos S., Margariti A., Exarchos X., Kokkonis G., et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2014, 60:62-68.
25. Romero A.I., Lagging M., Westin J., Dhillon A.P., Dustin L.B., Pawlotsky J.-M., et al. Interferon (IFN)-γ-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006, 194:895-903.
26. Diago M., Castellano G., García-Samaniego J., Pérez C., Fernández I., Romero M., et al. Association of pretreatment serum interferon γ inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006, 55:374-379.
27. Reiberger T., Aberle J.H., Kundi M., Kohrgruber N., Rieger A., Gangl A., et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther 2008, 13:969-976.
28. Sonneveld M.J., Arends P., Boonstra A., Hansen B.E., Janssen H.L.A. Serum levels of interferon-γ-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol 2013, 58:898-903.
29. Wang Y., Zhao C., Zhang L., Yu W., Shen C., Wang W., et al. Predictive value of interferon-γ inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon α therapy in chronic hepatitis B patients. Antiviral Res 2014, 103:51-59.
30. Castéra L., Vergniol J., Foucher J., Le Bail B., Chanteloup E., Haaser M., et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
31. Wursthorn K., Jaroszewicz J., Zacher B.J., Darnedde M., Raupach R., Mederacke I., et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol Off Publ Pan Am Soc Clin Virol 2011, 50:292-296.
32. Brunetto M.R. A new role for an old marker, HBsAg. J Hepatol 2010, 52:475-477.
33. Sarasin-Filipowicz M., Oakeley E.J., Duong F.H.T., Christen V., Terracciano L., Filipowicz W., et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008, 105:7034-7039.
34. Reijnders J.G.P., Rijckborst V., Sonneveld M.J., Scherbeijn S.M.J., Boucher C.A.B., Hansen B.E., et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011, 54:449-454.
35. Lucifora J., Xia Y., Reisinger F., Zhang K., Stadler D., Cheng X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014, 343:1221-1228.
36. Jiao Y., Li N., Chen X., Zhang T., Li H., Li W., et al. Acute HIV infection is beneficial for controlling chronic hepatitis B. Clin Infect Dis Off Publ Infect Dis Soc Am 2014, 60(1):128-134.
37. Yu M.-L., Lee C.-M., Chuang W.-L., Lu S.-N., Dai C.-Y., Huang J.-F., et al. HBsAg profiles in patients receiving peginterferon α-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. J Infect Dis 2010, 202:86-92.
38. Brunetto M.R., Oliveri F., Colombatto P., Moriconi F., Ciccorossi P., Coco B., et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010, 139:483-490.